Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ectopic Cushing's syndrome due to thymic neuroendocrine tumours: a systematic review.
Guerrero-Pérez F, Peiró I, Marengo AP, Teulé A, Ruffinelli JC, Llatjos R, Serrano T, Macia I, Vilarrasa N, Iglesias P, Villabona C. Guerrero-Pérez F, et al. Among authors: teule a. Rev Endocr Metab Disord. 2021 Dec;22(4):1041-1056. doi: 10.1007/s11154-021-09660-2. Epub 2021 May 7. Rev Endocr Metab Disord. 2021. PMID: 33961211 Review.
The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407).
Grande E, Teulé A, Alonso-Gordoa T, Jiménez-Fonseca P, Benavent M, Capdevila J, Custodio A, Vera R, Munarriz J, La Casta A, Díez JJ, Gajate P, Molina-Cerrillo J, Matos I, Cristóbal EM, Ruffinelli JC, Palacios J, García-Carbonero R. Grande E, et al. Among authors: teule a. Oncologist. 2020 Sep;25(9):745-e1265. doi: 10.1634/theoncologist.2020-0033. Epub 2020 Feb 11. Oncologist. 2020. PMID: 32045050 Free PMC article. Clinical Trial.
Genomically matched therapy in refractory colorectal cancer according to ESMO Scale for Clinical Actionability of Molecular Targets: experience of a comprehensive cancer centre network.
Mulet Margalef N, Castillo C, Mosteiro M, Pérez X, Aguilar S, Ruíz-Pace F, Gil M, Cuadra C, Ruffinelli JC, Martínez M, Losa F, Soler G, Teulé À, Castany R, Gallego R, Ruíz A, Garralda E, Élez E, Vivancos A, Tabernero J, Salazar R, Dienstmann R, Santos Vivas C. Mulet Margalef N, et al. Among authors: teule a. Mol Oncol. 2023 Sep;17(9):1908-1916. doi: 10.1002/1878-0261.13444. Epub 2023 Jun 12. Mol Oncol. 2023. PMID: 37097008 Free PMC article.
Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development.
Garcia-Carbonero R, Garcia-Figueiras R, Carmona-Bayonas A, Sevilla I, Teule A, Quindos M, Grande E, Capdevila J, Aller J, Arbizu J, Jimenez-Fonseca P; Spanish Cooperative Group of Neuroendocrine Tumors (GETNE). Garcia-Carbonero R, et al. Among authors: teule a. Cancer Metastasis Rev. 2015 Dec;34(4):823-42. doi: 10.1007/s10555-015-9598-5. Cancer Metastasis Rev. 2015. PMID: 26433592 Free PMC article. Review.
Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE).
Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Díaz-Pérez JA, Martínez Del Prado MP, Alonso Orduña V, Sevilla-García I, Villabona-Artero C, Beguiristain-Gómez A, Llanos-Muñoz M, Marazuela M, Alvarez-Escola C, Castellano D, Vilar E, Jiménez-Fonseca P, Teulé A, Sastre-Valera J, Benavent-Viñuelas M, Monleon A, Salazar R. Garcia-Carbonero R, et al. Among authors: teule a. Ann Oncol. 2010 Sep;21(9):1794-1803. doi: 10.1093/annonc/mdq022. Epub 2010 Feb 5. Ann Oncol. 2010. PMID: 20139156 Free article. Review.
Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE).
Grande E, Capdevila J, Castellano D, Teulé A, Durán I, Fuster J, Sevilla I, Escudero P, Sastre J, García-Donas J, Casanovas O, Earl J, Ortega L, Apellaniz-Ruiz M, Rodriguez-Antona C, Alonso-Gordoa T, Díez JJ, Carrato A, García-Carbonero R. Grande E, et al. Among authors: teule a. Ann Oncol. 2015 Sep;26(9):1987-1993. doi: 10.1093/annonc/mdv252. Epub 2015 Jun 10. Ann Oncol. 2015. PMID: 26063633 Free article. Clinical Trial.
Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin.
Capdevila J, Hernando J, Teule A, Lopez C, Garcia-Carbonero R, Benavent M, Custodio A, Garcia-Alvarez A, Cubillo A, Alonso V, Carmona-Bayonas A, Alonso-Gordoa T, Crespo G, Jimenez-Fonseca P, Blanco M, Viudez A, La Casta A, Sevilla I, Segura A, Llanos M, Landolfi S, Nuciforo P, Manzano JL. Capdevila J, et al. Among authors: teule a. Nat Commun. 2023 May 23;14(1):2973. doi: 10.1038/s41467-023-38611-5. Nat Commun. 2023. PMID: 37221181 Free PMC article. Clinical Trial.
High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome.
Mezquita L, Jové M, Nadal E, Kfoury M, Morán T, Ricordel C, Dhooge M, Tlemsani C, Léna H, Teulé A, Álvarez JV, Raimbourg J, Hiret S, Lacroix L, Menéndez M, Saldaña J, Brunet J, Lianes P, Coupier I, Auclin E, Recondo G, Friboulet L, Adam J, Green E, Planchard D, Frébourg T, Capellà G, Rouleau E, Lázaro C, Caron O, Besse B. Mezquita L, et al. Among authors: teule a. J Thorac Oncol. 2020 Jul;15(7):1232-1239. doi: 10.1016/j.jtho.2020.03.005. Epub 2020 Mar 14. J Thorac Oncol. 2020. PMID: 32179180 Free article.
89 results